Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
The company has convened its 2026 first class meeting of H shareholders for 27 February in Shanghai to vote on granting H-share investors assured entitlements tied to the planned spin-off and Hong Kong listing of subsidiary Fosun Adgenvax, underscoring Fosun Pharma’s use of capital-markets maneuvers to surface value. The resolution signals management’s intent to keep H shareholders engaged in the asset-unlocking transaction, potentially strengthening investor confidence ahead of the subsidiary’s proposed Main Board debut.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical is a diversified Chinese healthcare conglomerate spanning pharmaceuticals, medical devices, diagnostics and healthcare services, with a strategic focus on leveraging innovation and capital markets to grow its global footprint.
Average Trading Volume: 3,894,454
Technical Sentiment Signal: Sell
Current Market Cap: HK$73.4B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.